Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
Clinical trial NCT02659384 · COMPLETED
Trial details
- NCT number
- NCT02659384
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-23
- Primary completion
- 2021-06-01
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.